Effect of Genetic Polymorphism on the Clinical Outcome of Patients With Heart Failure (SNPs)
Effect of Genetic Polymorphism on the Clinical Outcome, Echocardiographic Parameters and Cardiac Biomarkers of Patients With Heart Failure
研究概览
地位
条件
详细说明
In the past decade there has been considerable progress in cardiovascular pharmacogenetics and pharmacogenomics. Although drug response variation in Heart Failure is likely multifactorial, pharmacogenetic variation may partially account for therapeutic failure contributing to the remaining high mortality in HF. Identifying novel gene variants affecting treatment response may reveal unrecognized pathways and new potential therapeutic targets. Few studies to date have attempted to assess the extent to which variation in drug response was exclusively due to genetic factors and therefore expounding the likely clinical benefit of using pharmacogenetics to guide HF therapy. One of the prerequisites to bridging this gap is to consider likely trial designs and criteria that will lead to a consensus upon using pharmacogenetics-based variants to guide therapy in clinical practice.
Another area gaining momentum is tailoring medication in response to biomarker levels as there is considerable evidence for the relationship between remodeling and fibrosis markers levels and worse prognosis in those with HF. Moreover,investigation into the proteomics of HF may also reveal variation that can be used to guide HF therapy hand-in-hand with biomarkers and pharmacogenomics, which would facilitate bridging the gap of genotype and phenotype. Disparity between genotype and phenotype may also account for the inconsistent results with current SNPs, further appreciation of this relationship would be a significant step forward.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Cairo、埃及
- Ain Shams University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Heart failure patients NYHA class II to IV.
- Left ventricular ejection fraction (LVEF) < 45%
- Written informed consent of the subject to participate in the study.
- Newly diagnosed patients who will be treated with BBs and ACEIs/or ARBs.
- Patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
- Age of 18 years to 80 years.
Exclusion Criteria:
- Contraindication to BBsor ACEIs.
- Contraindication to Spironolactone / Eplerenone.
- Patients who received previous treatment with Spironolactone / Eplerenone.
- Sig CAD, CABG, PCI, or valve surgery within 3 months.
- Mild-to-severe valvular stenosis or severe (grade III/IV) valvular regurgitation
- Pregnant or nursing women.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
---|
Cohort A
Newly diagnosed Heart Failure patients who will be treated with beta blockers (BB) and Angiotensin converting enzyme inhibitors (ACEIs)/or Angiotensin receptor blockers (ARBs) for the first time.
|
Cohort B
Heart Failure patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
RAAS genes and Clinical Outcome
大体时间:6 months
|
Association between RAAS genetic polymorphism and clinical response, Cardiac remodeling and Fibrosis biomarkers and echocardiographic outcome of patients with heart failure.
|
6 months
|
Adrenergic receptors genes and Clinical Outcome
大体时间:6 months
|
Association between Adrenergic receptors genetic polymorphism and clinical response, Cardiac remodeling and Fibrosis biomarkers and echocardiographic outcome of patients with heart failure.
|
6 months
|
Cardiac Fibrosis genes and Clinical Outcome
大体时间:6 months
|
Association between Cardiac Fibrosis genes genetic polymorphism and clinical response, Cardiac remodeling and Fibrosis biomarkers and echocardiographic outcome of patients with heart failure.
|
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Overall patients' clinical outcome
大体时间:12 months
|
Potential interaction between these target genes polymorphism and the overall patients' clinical outcome, mortality and response to treatment of heart failure.
|
12 months
|
合作者和调查者
调查人员
- 首席研究员:Neven M. Sarhan, MSc、Misr International University
- 学习椅:Nagwa A. Sabri, PhD、Ain Shams University
- 研究主任:Mona F. Schaalan, PhD、Misr International University
- 研究主任:Lamiaa M. Elwakeel, PhD、Ain Shams University
- 研究主任:Hazem M. Khorshid, MD、Ain Shams University
- 研究主任:Mohamed H. Solyaman, PhD、Ain Shams University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.